ABT Abbott LaboratoriescompanySEC Filings & Insider Trading Activity 2026
Latest Abbott Laboratories (ABT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 20, 2026, a 10-Q quarterly report filed on October 29, 2025, an 8-K current report filed on April 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Abbott Laboratories (ABT) (SEC CIK 1800), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Risk Factors
- • IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
- • Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
Management Discussion & Analysis
- • Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
- • Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
Business Overview
- • Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
- • Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • Section 'risk_factors' was empty or not found.
Management Discussion & Analysis
- • Revenue $11.37B Q3 2025, up 6.9% YoY vs $10.64B Q3 2024, excluding FX impact increase 5.5%
- • Gross margin 51.7% Q3 2025 vs 51.4% Q3 2024, Nine months margin 52.4% vs 51.0% YoY
Annual Reports Archive10-K
AI-powered analysis of Abbott Laboratories (ABT) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Abbott Laboratories (ABT) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Abbott Laboratories (ABT) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $43.7B | $40.1B | $42.0B | $44.3B |
| Operating Income | $8.4B | $6.5B | $6.8B | $8.1B |
| Net Income | $6.9B | $5.7B | $13.4B | $6.5B |
| Op. Margin | 19.2% | 16.2% | 16.3% | 18.2% |
| Net Margin | 15.9% | 14.3% | 31.9% | 14.7% |
| Balance Sheet | ||||
| Total Assets | $74.4B | $73.2B | $81.4B | $86.7B |
| Equity | $36.7B | $38.6B | $47.7B | $52.1B |
| ROE | 18.9% | 14.8% | 28.1% | 12.5% |
Source: XBRL financial data from Abbott Laboratories (ABT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 27, 2026 | — | — | — |
8-K | Apr 17, 2026 | — | — | — |
8-K | Apr 16, 2026 | — | — | — |
8-K | Mar 23, 2026 | — | — | — |
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Feb 20, 2026 | — | — | |
10-K | Feb 20, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 22, 2026 | — | — | |
8-K | Dec 12, 2025 | — | — | |
10-Q | Oct 29, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 30, 2025 | Jun 30, 2025 | — | |
10-Q | Apr 30, 2025 | Mar 31, 2025 | — | |
10-K | Feb 21, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 31, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Feb 16, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 1, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 17, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 1, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 2, 2022 | Jun 30, 2022 | — | |
10-Q | May 3, 2022 | Mar 31, 2022 | — |
Frequently Asked Questions
What are the latest ABT SEC filings in 2026?
Abbott Laboratories (ABT) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on October 29, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ABT file its most recent 10-K annual report?
Abbott Laboratories (ABT) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ABT 10-Q quarterly reports?
Abbott Laboratories (ABT)'s most recent 10-Q quarterly report was filed on October 29, 2025. SignalX displays every ABT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ABT filed recently?
Abbott Laboratories (ABT)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ABT insider trading activity (Form 4)?
SignalX aggregates every ABT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ABT file with the SEC?
Abbott Laboratories (ABT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ABT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Abbott Laboratories (ABT).
What is ABT's SEC CIK number?
Abbott Laboratories (ABT)'s SEC CIK (Central Index Key) number is 1800. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1800 to look up all ABT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ABT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Abbott Laboratories (ABT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Abbott Laboratories SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 42+ filings.